Llwytho...
Fenofibrate modified-release pellets with lag phase and high oral bioavailability
PURPOSE: Fenofibrate and statin combination therapy is highly recommended by the current clinical guidelines for treatment of mixed dyslipidemia. In this study, an innovative delayed-release preparation of fenofibrate was designed to reduce the risk of muscle toxicity, caused by simultaneous adminis...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Drug Des Devel Ther |
|---|---|
| Prif Awduron: | , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6307495/ https://ncbi.nlm.nih.gov/pubmed/30613135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S179266 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|